Evidence map›Paper›PMID 30658456›Full record

ArticleJournal of clinical medicine2019

Driving Type 2 Diabetes Risk Scores into Clinical Practice: Performance Analysis in Hospital Settings.

Antonio Martinez-Millana, María Argente-Pla, Bernardo Valdivieso Martinez, Vicente Traver Salcedo, Juan Francisco Merino-Torres

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Machine learning for diabetes clinical decision support: a review.Advances in computational intelligence · 2022
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Antonio Martinez-MillanaITACA, Universitat Politècnica de València, Camino de Vera s/n, 46022 Valencia, Spain. anmarmil@itaca.upv.es.ORCID 0000-0003-1056-5067
María Argente-PlaEndocrinology and Nutrition Department, University Hospital La Fe, Avinguda de Fernando Abril Martorell, 106, 46026 València, Spain. mariaargentepla@gmail.com.
Bernardo Valdivieso MartinezUnidad Mixta de Reingeniería de Procesos Sociosanitarios, Instituto de Investigación Sanitaria del Hospital Universitario y Politecnico La Fe Bulevar Sur S/N, 46026 Valencia, Spain. valdivieso_ber@gva.es.
Vicente Traver SalcedoITACA, Universitat Politècnica de València, Camino de Vera s/n, 46022 Valencia, Spain. vtraver@itaca.upv.es.ORCID 0000-0003-1806-8575
Juan Francisco Merino-TorresEndocrinology and Nutrition Department, University Hospital La Fe, Avinguda de Fernando Abril Martorell, 106, 46026 València, Spain. merino_jfr@gva.es.

Funding

European Commission 600914
6 · The paper itself

Abstract

Electronic health records and computational modelling have paved the way for the development of Type 2 Diabetes risk scores to identify subjects at high risk. Unfortunately, few risk scores have been externally validated, and their performance can be compromised when routine clinical data is used. The aim of this study was to assess the performance of well-established risk scores for Type 2 Diabetes using routinely collected clinical data and to quantify their impact on the decision making process of endocrinologists. We tested six risk models that have been validated in external cohorts, as opposed to model development, on electronic health records collected from 2008-2015 from a population of 10,730 subjects. Unavailable or missing data in electronic health records was imputed using an existing validated Bayesian Network. Risk scores were assessed on the basis of statistical performance to differentiate between subjects who developed diabetes and those who did not. Eight endocrinologists provided clinical recommendations based on the risk score output. Due to inaccuracies and discrepancies regarding the exact date of Type 2 Diabetes onset, 76 subjects from the initial population were eligible for the study. Risk scores were useful for identifying subjects who developed diabetes (Framingham risk score yielded a c-statistic of 85%), however, our findings suggest that electronic health records are not prepared to massively use this type of risk scores. Use of a Bayesian Network was key for completion of the risk estimation and did not affect the risk score calculation (

Indexed as

clinical datapredictionRisk scoresscreeningT2DM

Identifiers

PMID30658456
PMCPMC6352264

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.